Table 1.
Overview S. aureus isolates collected in three different field studies in which extended therapies were used for treatment of IMIs
| Extended therapy with | |||
|---|---|---|---|
| Cephapirin | Pirlimycin | Ceftiofur | |
| Total number of casesa | 29 | 40 | 17 |
| Based on bacteriology | |||
| Cases in which S. aureus was eliminated | 12 | 33 | 9 |
| Cases in which S. aureus was isolated after therapy | 17 | 7 | 8 |
| Proportion of isolates that were eliminated (%) | 41.3 | 82.5 | 52.9 |
| Based on VNTR analysis | |||
| Isolates that were eliminated or that were distinct by VNTR before and after therapy | 19 | 34 | 9 |
| Isolates from persistent cases (same VNTR before and after therapy) | 10 | 6 | 8 |
| Proportion of isolates that were eliminated (%) | 65.5 | 85.0 | 52.9 |
| Number of isolates characterized in this studyb | |||
| Isolates from cured cases | 12 | 23c | 9 |
| Isolates from persistent cases (VNTR-confirmed)c | 10 | 6 | 8 |
aCases are quarters infected with S. aureus. Isolates from cured cases are revealed when one S. aureus isolate is found before treatment but no S. aureus is detected after the end of treatment. Persistent cases are revealed when one S. aureus isolate is found before treatment and at least one S. aureus isolate is also found after the end of treatment.
bCases that were not validated as persistent (possible new infections by a different S. aureus isolate) were excluded of the study. When multiple isolates were collected from the same cow (different quarters), only one isolate was selected for the study.
cOnly the isolates collected before treatment were used for the rest of the study.